Ping Shao, MS

Regeneron Pharmaceuticals, Inc.

Poster(s):

• ((SLA-025)) (SLA-025) Second Primary Malignancy in Patients with Diffuse Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy and Other Systemic Anti-Cancer Therapy: A Real-World Evidence from a Large US National Claims Database
  Sunday, August 24, 2025

  12:15 PM - 1:15 PM ET

• ((A-289)) (A-289) Application of Administrative Claims-Based Algorithms to Characterize Pregnancy in Atherosclerotic Cardiovascular Disease or Likely Familial Hypercholesterolemia
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• ((B-027)) (B-027) Incidence of cardiac events in patients with moderate to severe COPD: a retrospective analysis of US claims data
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET

• ((B-284)) (B-284) Incidence of serious infections in patients with moderate to severe COPD: a retrospective analysis of US claims data
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET

• ((C-016)) (C-016) Characterizing dupilumab-naïve patients with bullous pemphigoid using US administrative claims data
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• ((C-214)) (C-214) Second Primary Malignancy in Patients with Multiple Myeloma Receiving Chimeric Antigen Receptor T-Cell Therapy and Other Systemic Anticancer Therapy: A Comparative Study Using a Real-World Database
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET